Duke University School of Medicine

Biogen and UCB may have a differentiated treatment for systemic lupus erythematosus (SLE) based on detailed results from the first Phase III clinical trial of the anti-CD40L antibody dapirolizumab peg

Milestone Pharmaceuticals, Inc. ’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment f

Vor Hopes NCI’s CAR-T Candidate Is Synergistic With Lead AML Therapy PureTech Health plc -backed Vor Biopharma Inc. said on 11 November that it has licensed a clinical-stage chimeric antigen recept

Technology transfer from universities and other non-profit research institutions to private sector firms is core to the modern biopharma industry, but before the enactment of the Bayh-Dole Act in 1980